Alfresa Holdings Corporation (2784.T)
- Previous Close
1,920.00 - Open
1,900.00 - Bid 1,923.00 x --
- Ask 1,925.00 x --
- Day's Range
1,897.00 - 1,930.50 - 52 Week Range
1,897.00 - 2,473.50 - Volume
483,800 - Avg. Volume
543,831 - Market Cap (intraday)
349.853B - Beta (5Y Monthly) --
- PE Ratio (TTM)
13.05 - EPS (TTM)
147.46 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield 68.00 (3.54%)
- Ex-Dividend Date Sep 29, 2025
- 1y Target Est
2,173.33
Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. It is involved in the ethical pharmaceuticals wholesaling business that offers diagnostic reagents and medical devices/equipment to hospitals, clinics, and dispensing pharmacies. The company also engages in self-medication products wholesaling business that offers over-the-counter drugs, including health foods, supplements, and other products to drug stores and pharmacies. In addition, it manufactures and markets active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices, as well as undertakes contract manufacturing of pharmaceuticals. Further, the company's medical-related business includes its dispensing pharmacy and other medical-related businesses. The company was incorporated in 2003 and is based in Tokyo, Japan.
www.alfresa.comRecent News: 2784.T
View MorePerformance Overview: 2784.T
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2784.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2784.T
View MoreValuation Measures
Market Cap
349.03B
Enterprise Value
208.68B
Trailing P/E
13.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.12
Price/Book (mrq)
0.72
Enterprise Value/Revenue
0.07
Enterprise Value/EBITDA
3.80
Financial Highlights
Profitability and Income Statement
Profit Margin
0.93%
Return on Assets (ttm)
1.65%
Return on Equity (ttm)
5.70%
Revenue (ttm)
2.96T
Net Income Avi to Common (ttm)
27.39B
Diluted EPS (ttm)
147.46
Balance Sheet and Cash Flow
Total Cash (mrq)
177.09B
Total Debt/Equity (mrq)
7.37%
Levered Free Cash Flow (ttm)
-3.56B